Fund managers

o2h Ventures, a specialist biotech fund manager based in the heart of the thriving biotech community in Cambridge, UK. We invest in early-stage biotech companies involved in novel drug discovery, enabling service tools, and AI/ML technologies. Currently, we have two tax-efficient human health funds open for investment: the Enterprise Investment Scheme and the Seed Enterprise Investment Scheme.

To date, through our funds, we have invested over $10 million in 35+ early-stage biotech companies, empowering impactful research addressing unmet medical needs in areas such as cancer, depression, diseases of the ear and eye, psoriasis, idiopathic pulmonary fibrosis, anti-ageing, and infectious diseases. For more details, please see – www.o2hventures.com

Founded in 2015, Velocity looks to invest in high capital appreciation digital distribution business providing value beyond the provision of capital. For the businesses that the fund looks to invest in, there is a point in time when marketing becomes their largest expense. Getting it right can be transformational for these businesses, whilst getting it wrong can be a very costly mistake. Through the significant experience of the founders of Velocity, support in and around marketing provides a cornerstone of value-add provided to investee companies, although it is by no means limited to this. Each potential fund investment goes through a rigorous six-stage selection process, which includes an assessment of market need, given that there being insufficient market need for a particular product or service is, according to CBInsights, the second most common reason why businesses fail. Velocity has a multidisciplinary team with a balance between those with entrepreneurial experience (having started, scaled and exited businesses) and professional experience including fund management, accountancy and law. Our view is that the breadth of team experience enables us to provide holistic support to the businesses we invest in, providing them with an unfair advantage and thereby a greater likelihood of success.

Triple Point is an independent investment management partnership founded in 2004 with expertise in asset and project finance, private equity, portfolio management and structuring.
In addition to seeking risk adjusted returns for investors, a strong emphasis is placed on liquidity. Funds are typically raised from private investors and may be held in a number of tax advantaged vehicles including Venture Capital Trusts (VCTs) and investments qualifying under the Enterprise Investment Scheme (EIS). Many also qualify for Inheritance Tax Business Property Relief.
All of Triple Point’s investment products engage our track record in sourcing, executing and exiting investments for clients. Our strong reputation in this field ensures a productive pipeline of attractive opportunities.

TIME provides tax efficient investment solutions and we’re proud to say we’re rather good at it with more than £500 million of assets under management. What stands us apart in our market is our focus on seeking consistent stable returns for our investors, which we deliver through a defensive investment strategy. The TIME senior team has been involved in the management of Enterprise Investment Schemes since 2001 and was one of the original members of the EISA.

The specialist investment team at TIME, who combined have more than 200 years of experience, concentrate on identifying investments which are primarily asset backed, with strong risk management and a focus on capital preservation. The team has established a rigorous review process for potential investment opportunities, as well as a network of third party professionals on which it can call on for independent comment and insight.

Symvan Capital is a leading and trusted Venture Capital Fund Manager based in London, investing in innovative technology companies across the UK. We focus on ventures solving real-world problems through AI and other enabling technologies, offering investors access to our flagship evergreen EIS and SEIS funds – and the attractive tax reliefs these schemes provide.

With a proven track record, a commitment to integrity and transparency, and a focus on long-term value creation, Symvan curates opportunities that scale, disrupt industries and create long term value.

At Symvan, we don’t just invest – we partner. By working directly with founding teams, we help high-potential ventures overcome challenges and unlock scalable growth. Our hands-on, collaborative approach has led to one of the strongest investment performance records in the tax-efficient space, including one of the lowest EIS failure rates in the market, recognised by investors, founders, and independent research platforms alike.